Affimed NV (NASDAQ:AFMD) Receives Average Rating of “Buy” from Analysts

Affimed NV (NASDAQ:AFMD) has been assigned a consensus recommendation of “Buy” from the six analysts that are covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $7.39.

Several equities analysts have recently issued reports on the stock. ValuEngine raised shares of Affimed from a “sell” rating to a “hold” rating in a report on Wednesday, August 28th. Zacks Investment Research lowered shares of Affimed from a “buy” rating to a “hold” rating in a report on Thursday, August 8th. Finally, Laidlaw set a $10.00 price target on shares of Affimed and gave the company a “buy” rating in a report on Wednesday, July 3rd.

Shares of AFMD stock traded up $0.09 on Friday, hitting $2.74. The stock had a trading volume of 256,108 shares, compared to its average volume of 719,042. Affimed has a twelve month low of $2.52 and a twelve month high of $5.08. The firm has a market cap of $170.95 million, a P/E ratio of -7.21 and a beta of 2.85. The company has a current ratio of 3.48, a quick ratio of 3.47 and a debt-to-equity ratio of 0.02. The company has a fifty day moving average price of $2.99 and a two-hundred day moving average price of $3.18.

Affimed (NASDAQ:AFMD) last announced its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.16). Affimed had a negative net margin of 30.87% and a negative return on equity of 30.94%. The company had revenue of $4.50 million during the quarter, compared to analyst estimates of $6.46 million. On average, analysts expect that Affimed will post -0.08 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the company. CIBC World Markets Inc. boosted its stake in Affimed by 17.7% in the 1st quarter. CIBC World Markets Inc. now owns 66,500 shares of the biopharmaceutical company’s stock worth $279,000 after purchasing an additional 10,000 shares during the period. State of New Jersey Common Pension Fund D acquired a new position in Affimed in the 2nd quarter worth $29,000. Weiss Asset Management LP boosted its stake in Affimed by 69.7% in the 1st quarter. Weiss Asset Management LP now owns 29,877 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 12,271 shares during the period. Parametric Portfolio Associates LLC acquired a new position in Affimed in the 2nd quarter worth $41,000. Finally, Mackenzie Financial Corp acquired a new position in Affimed in the 2nd quarter worth $47,000. 51.25% of the stock is owned by institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

Recommended Story: What are momentum indicators and what do they show?

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.